Sinovac Biotech Earnings: What Investors Should Watch

Sinovac Biotech (NASDAQ:SVA) will report earnings after markets close on Tuesday, August 13th. Sinovac Biotech Ltd. researches, develops, manufactures, and markets various vaccines, including flu vaccines and vaccines for Hepatitis A. The Company’s products are sold in the Peoples Republic of China and other countries.

Here is your Cheat Sheet to Sinovac Biotech Earnings:

Earnings Expectations: Analysts expect earnings of $-0.06 per share on revenues of $11.62 million.

Analyst Trends:

Analysts have a more positive outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has risen from a loss of $0.06 to a loss $0.05. For the current year, the average estimate is a loss of $0.18, which is better than the estimate ninety days ago.

Earnings Trends:

Here’s how Sinovac Biotech has been performing on an annual basis:

Fiscal Year 2008 2009 2010 2011 2012
Revenue ($) in millions 46 84 33 57 49
Diluted EPS ($) 0.19 0.46 -0.16 -0.02 -0.29

Next, our CHEAT SHEET investing framework asks us to drill down to the recent quarterly data:

Quarter Jun. 30, 2012 Sep. 30, 2012 Dec. 31, 2012 Mar. 31, 2013
Revenue ($) in millions 9.36 14.29 18.95 10.05
Diluted EPS ($) -0.02 -0.06 -0.10 -0.04

Past Performance:
Sinovac Biotech has beat analyst estimates 2 times in the past four quarters. This is not consistent enough to get bullish yet.

“E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our successful CHEAT SHEET investing framework. Don’t waste another minute – click here to discover our CHEAT SHEET stock picks now!

(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at]